Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
Eur J Cancer. 2023 Dec;195:113386. Epub 2023 Oct 14.
A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)
Eur J Cancer. 2023 Nov;193:113312. Epub 2023 Aug 28
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)
J Clin Oncol. 2023 Oct 20:JCO2301891. Online ahead of print.
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
J Clin Oncol. 2023 Sep 12;JCO2202786. Online ahead of print.
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): In-Depth Analysis of Nintendanib Arm from the KCSG HN 15-16 TRIUMPH Trial.
Cancer Res Treat. 2023 Jul 20. Online ahead of print
Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.
ESMO Open. 2023 Jun 27;8(4):101588. Online ahead of print.
Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06).
Korean J Intern Med. 2023 Jun 26. Online ahead of print.
